Q3 EPS Forecast for NewAmsterdam Pharma Raised by Analyst

Key Points

• Leerink Partners has raised its Q3 2025 earnings per share estimate for NewAmsterdam Pharma from ($0.47) to ($0.41), indicating increased optimism for the company's financial performance.
• A recent report from Citigroup and other analysts includes a "buy" rating for NewAmsterdam Pharma, with target prices ranging from $27.00 to $44.00, suggesting strong investor confidence.
• NewAmsterdam Pharma reported a quarterly loss of ($0.15) EPS, outperforming expectations significantly, and generated revenues of $19.15 million, far exceeding the consensus estimate of $1.44 million.

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) - Equities researchers at Leerink Partnrs increased their Q3 2025 earnings per share estimates for shares of NewAmsterdam Pharma in a report released on Wednesday, August 6th. Leerink Partnrs analyst R. Ruiz now expects that the company will earn ($0.41) per share for the quarter, up from their previous forecast of ($0.47). The consensus estimate for NewAmsterdam Pharma's current full-year earnings is ($1.75) per share. Leerink Partnrs also issued estimates for NewAmsterdam Pharma's Q4 2025 earnings at ($0.53) EPS, FY2025 earnings at ($1.57) EPS, FY2026 earnings at ($1.86) EPS, FY2027 earnings at ($1.82) EPS and FY2028 earnings at ($0.43) EPS.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.37. NewAmsterdam Pharma had a negative return on equity of 27.27% and a negative net margin of 259.07%. The firm had revenue of $19.15 million during the quarter, compared to analysts' expectations of $1.44 million.

Several other analysts have also recently issued reports on the company. The Goldman Sachs Group initiated coverage on NewAmsterdam Pharma in a report on Thursday, July 17th. They issued a "neutral" rating and a $27.00 target price for the company. Stifel Nicolaus initiated coverage on NewAmsterdam Pharma in a report on Tuesday, June 10th. They issued a "buy" rating and a $44.00 target price for the company. Citigroup initiated coverage on NewAmsterdam Pharma in a report on Tuesday, June 17th. They issued a "buy" rating and a $42.00 target price for the company. Cantor Fitzgerald initiated coverage on NewAmsterdam Pharma in a report on Wednesday, June 4th. They issued an "overweight" rating and a $42.00 target price for the company. Finally, Needham & Company LLC restated a "buy" rating and issued a $40.00 target price on shares of NewAmsterdam Pharma in a report on Thursday, June 12th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat, NewAmsterdam Pharma has a consensus rating of "Moderate Buy" and an average price target of $41.20.

NewAmsterdam Pharma Stock Performance

Shares of NAMS traded down $0.97 during trading hours on Monday, hitting $24.80. 329,765 shares of the stock were exchanged, compared to its average volume of 875,526. NewAmsterdam Pharma has a 12-month low of $14.06 and a 12-month high of $27.29. The company has a market cap of $2.78 billion, a price-to-earnings ratio of -15.31 and a beta of -0.02. The stock's 50-day moving average price is $21.09 and its two-hundred day moving average price is $20.06.

Insider Activity

In related news, COO Douglas F. Kling sold 100,000 shares of the stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $19.29, for a total transaction of $1,929,000.00. Following the transaction, the chief operating officer owned 44,000 shares of the company's stock, valued at approximately $848,760. This represents a 69.44% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director James N. Topper bought 8,584 shares of the firm's stock in a transaction that occurred on Monday, June 16th. The shares were purchased at an average cost of $19.50 per share, for a total transaction of $167,388.00. Following the purchase, the director owned 3,022,153 shares in the company, valued at $58,931,983.50. This represents a 0.28% increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 12,835 shares of company stock worth $248,134 and have sold 198,612 shares worth $4,025,887. 20.84% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On NewAmsterdam Pharma

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Quarry LP purchased a new position in shares of NewAmsterdam Pharma in the 1st quarter valued at about $25,000. GF Fund Management CO. LTD. purchased a new position in shares of NewAmsterdam Pharma in the 4th quarter valued at about $50,000. National Bank of Canada FI purchased a new position in shares of NewAmsterdam Pharma in the 4th quarter valued at about $51,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of NewAmsterdam Pharma by 19.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company's stock valued at $80,000 after buying an additional 596 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of NewAmsterdam Pharma by 130.4% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,990 shares of the company's stock valued at $123,000 after buying an additional 3,390 shares during the period. Hedge funds and other institutional investors own 89.89% of the company's stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.